IDXX vs. NVST, ZTS, ISRG, BSX, SYK, MDT, BDX, EW, RMD, and DXCM
Should you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include Envista (NVST), Zoetis (ZTS), Intuitive Surgical (ISRG), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), ResMed (RMD), and DexCom (DXCM). These companies are all part of the "medical" sector.
IDEXX Laboratories vs. Its Competitors
Envista (NYSE:NVST) and IDEXX Laboratories (NASDAQ:IDXX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.
87.8% of IDEXX Laboratories shares are held by institutional investors. 0.7% of Envista shares are held by insiders. Comparatively, 1.0% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, IDEXX Laboratories had 27 more articles in the media than Envista. MarketBeat recorded 31 mentions for IDEXX Laboratories and 4 mentions for Envista. IDEXX Laboratories' average media sentiment score of 1.60 beat Envista's score of 0.74 indicating that IDEXX Laboratories is being referred to more favorably in the news media.
IDEXX Laboratories has higher revenue and earnings than Envista. IDEXX Laboratories is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.
IDEXX Laboratories has a net margin of 24.41% compared to Envista's net margin of 2.11%. IDEXX Laboratories' return on equity of 64.42% beat Envista's return on equity.
Envista presently has a consensus target price of $20.92, indicating a potential downside of 1.21%. IDEXX Laboratories has a consensus target price of $649.44, indicating a potential upside of 0.71%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe IDEXX Laboratories is more favorable than Envista.
Envista has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.
Summary
IDEXX Laboratories beats Envista on 15 of the 16 factors compared between the two stocks.
Get IDEXX Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IDEXX Laboratories Competitors List
Related Companies and Tools
This page (NASDAQ:IDXX) was last updated on 9/17/2025 by MarketBeat.com Staff
